Hikma Manages To Stay Flat In 2022 Despite Generics Pressures

Annual Results See Injectables And Brands Success Offsetting Struggling Generics Unit

As expected, Hikma’s generics business saw a significant slide in 2022 – but contributions from its successful injectables and brands divisions helped to stop an overall sales decline for the firm.

Finger pushing down on scales, balancing piles of coins
Growing returns from injectables and brands are helping to balance downwards pressures on Hikma’s generics business • Source: Shutterstock

Hikma has made no secret of its lowered expectations for its generics business in 2022. Having downgraded its forecasts multiple times over the course of last year (Also see "Hikma Eyes Return To Growth After Further Cutting Generics Forecasts" - Generics Bulletin, 4 August, 2022.), the firm has prepared investors and analysts for a rocky 12-month report.

And now, publishing its annual results, the company has confirmed that it has seen “a tough year for this business,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business